Reader’s guide · First edition · September 2026 · Revised October 1, 2026
BPC-157 / TB-500
A guide to the healing blend vendors call the Wolverine stack: two peptides sold on the same mechanism, one with thin human evidence and one with none, never tested together
The BPC-157 and TB-500 blend is the original peptide stack and still the most popular one for injuries: ten milligrams of each, freeze-dried together in one vial, injected nightly for a few weeks after a strain, a tear, or a surgery. Vendors describe the two as a team, one for tendon and gut and one for muscle, and the name Wolverine promises a superhero's recovery. This guide covers what is in the vial, what each peptide has and has not shown in people, why the division of labor is a sales story rather than a finding, what the blend arithmetic does to each dose, and where both peptides stand after a year of FDA decisions.
Who this is for
Written for adults who are using, or being offered, the BPC-157 and TB-500 blend for an injury, a surgery, or general recovery. It summarizes the published record for each peptide and the regulatory position as of the edition date. It is not medical advice.
Two peptides with different origins and, sellers say, different jobs. BPC-157 is a fifteen-amino-acid fragment of a protein in human gastric juice, studied for thirty years in one Croatian laboratory as a healing agent for gut and tendon. TB-500 is a seven-amino-acid fragment of thymosin beta-4, a protein every cell uses to manage its scaffolding, and the segment sold is the part that binds actin. Vendors freeze-dry equal amounts of the two together and sell the vial under a name borrowed from a comic book.
| Ingredient | Amount | What it is sold for | In this series |
|---|---|---|---|
| BPC-157 | 10 mg | Tendon, ligament, gut, and general tissue healing | SKU 3, the BPC-157 guide |
| TB-500 | 10 mg | Muscle recovery, flexibility, tendon healing | The field guide; this title |
Vendors also sell 5 + 5 mg and 15 + 15 mg vials, and some a 1:2 ratio with more TB-500. Every figure in this guide is for the 10 + 10 mg vial unless stated.
- Forms
- Freeze-dried blend vials of 10, 20, or 30 mg from research vendors, reconstituted by the buyer and injected subcutaneously, often near the injury; the same two peptides in separate vials; both inside the GLOW and KLOW blends
- Price as sold
- About $40 to $120 for a 10 mg (5 + 5) vial and $60 to $150 for 20 mg (10 + 10), roughly a month of the common protocol
- Status
- Neither peptide is approved anywhere. Both left FDA's Category 2 list in April 2026 and were recommended for the compounding list by an advisory committee in July; neither is listed, and the blend has no pathway regardless.
- Anti-doping
- Both prohibited by WADA at all times; TB-500 is detectable for weeks after a dose
The name is the product
Wolverine heals from anything overnight. The vial contains two peptides whose human record, combined, is three small uncontrolled reports and no controlled trial of either, alone or together. Buy the name knowing that is what it is.
| Peptide | Human studies | Result | Grade |
|---|---|---|---|
| BPC-157 | Three small uncontrolled reports: 16 knee injections, 12 bladder instillations, 2 healthy adults infused. About 30 people in total, in one alternative-medicine journal | Most reported improvement; no comparison group in any of them | C |
| TB-500 (the fragment) | None. No published human study of the seven-amino-acid fragment for any purpose | Nothing to report | D |
| Thymosin beta-4 (the full protein) | Small trials by its developer: 73 patients with venous leg ulcers, a Phase 2 in a rare blistering disease, and eye-surface trials including a Phase 3 that missed its endpoint and a small one that did not | Mixed; a safety record at high intravenous doses; no approval anywhere | B for the parent, which the fragment does not inherit |
| The pair | None. One of the BPC-157 knee reports added thymosin beta-4 in some injections, with no comparison | Nothing separable | None |
The animal record is another matter: hundreds of rodent studies of BPC-157, almost all from one laboratory, and a thick literature on thymosin beta-4 in wound and heart models. Rat results are the reason people try these; they are not evidence that they work in people.
Registered trials recruiting for either peptide as of this edition
What would count as evidence
A randomized trial against placebo or standard care in a defined injury, such as Achilles tendinopathy or a rotator cuff repair, with a pre-registered outcome and independent funding. None exists for either peptide, and for the pair no one has proposed one.
Vendors present the two as complementary: BPC-157 for tendons, ligaments, and gut; TB-500 for muscle and flexibility. Read the animal literature and the split disappears. Both are proposed to work by the same two processes, growing new blood vessels into injured tissue and drawing repair cells to it. Two peptides on the same pathway are overlapping, not complementary, and no study has tested whether overlapping them adds anything.
| Test for a rational combination | BPC-157 / TB-500 |
|---|---|
| Each part has evidence alone in humans | One has three uncontrolled reports; the other has none |
| The parts act by different mechanisms | Both are sold on angiogenesis and cell migration; the animal work does not support separate jobs |
| The pair was tested at the ratio sold | Never. One to one is the ratio that is easy to manufacture |
| Stability of the mixture | Untested for the freeze-dried blend or the reconstituted vial |
If you believe in both, buy them separately
Separate vials let a user run BPC-157 daily and TB-500 twice weekly, the way each is sold alone, change one without the other, and stop one if something goes wrong. The blend forces a daily dose of TB-500 that its own protocol does not use and removes any way to tell which peptide caused a reaction.
How it is used, and what each peptide actually gets10
| Protocol | Instruction | What is known |
|---|---|---|
| Blend vial | 20 mg vial with 2 mL of water; 6 to 10 units nightly, five nights on and two off, for 4 to 12 weeks, often injected near the injury | No human study; "near the injury" has no established rationale for peptides that enter the bloodstream |
| Separate vials | BPC-157 250 to 500 mcg daily; TB-500 2 to 2.5 mg twice weekly for 4 to 6 weeks, then weekly | The two protocols the blend collapses into one |
| Oral BPC-157 | 250 to 500 mcg capsules daily, sometimes alongside the injected blend | Survives gastric acid in animals; human absorption unmeasured |
| Cycling | 4 to 12 weeks, then a break | Custom; no data |
What the next tables are, and are not
They express the vendor protocol for the 20 mg blend vial as sold, so the arithmetic can be checked, and they show what each peptide receives at that dose. Nothing here has been tested in a human trial, neither peptide may lawfully be compounded, and a research-chemical blend's identity, ratio, and sterility are unverified.
- Vial
- 20 mg blend (10 mg BPC-157, 10 mg TB-500), as sold; identity, ratio, and quantity unverified
- Water added
- 2 mL bacteriostatic water, the vendors' own instruction
- Concentration
- 10 mg/mL of blend, which is 5 mg/mL (5,000 mcg/mL) of each peptide. One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe with half-unit marks; the standard draw is 10 units
| Weeks | Nightly dose | Draw | Units | Used per 4 weeks |
|---|---|---|---|---|
| 1–2 | 0.6 mg of blend (300 mcg of each) | 0.06 mL | 6 | 12 mg |
| 3–8 | 1 mg of blend (500 mcg of each) | 0.1 mL | 10 | 20 mg (1 vial) |
| After 8 | Stop and reassess; some run to 12 |
Twenty injection nights per 4 weeks. The ramp is custom; the vendors' calculators default to 10 units.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
| Peptide | Per 10-unit dose | Per week (5 nights) | Sold alone at | Share |
|---|---|---|---|---|
| BPC-157 | 500 mcg | 2.5 mg | 250 to 500 mcg daily | A full dose |
| TB-500 | 500 mcg | 2.5 mg | 4 to 5 mg a week loading, then 2 to 2.5 mg a week | Half the loading dose; a full maintenance dose, spread daily |
The blend gives TB-500 every night in fifths instead of twice a week in whole doses. Nobody knows whether that matters, because nobody has tested either schedule.
- Injecting near the injury is folklore. The animal studies dosed systemically, and a subcutaneous injection enters the bloodstream either way.
- The 1:2 blends with double TB-500 exist because some users want the loading dose; they halve the BPC-157 share instead. There is no right ratio because there is no data.
- Reconstituted vials have no tested beyond-use date. Refrigerate, keep it dark, and assume degradation within weeks.
The two peptides have moved through the FDA's compounding process in lockstep, and both are further along than any other peptide in this series that is not an approved drug. Neither is approved for anything. The live question is whether pharmacies may compound them, and the answer this year changed from no to not yet.
| Date | Event |
|---|---|
| 2022 | WADA adds BPC-157 to the Prohibited List; TB-500 and thymosin beta-4 derivatives were already prohibited |
| Sep 2023 | FDA places BPC-157 in Category 2, citing impurity and immune concerns: not to be compounded |
| 2025 | FDA warning letters to sellers marketing BPC-157 and other peptides for human use under research labels |
| Apr 2026 | BPC-157, TB-500, and ten other peptides leave Category 2 after their nominations are withdrawn |
| Jul 2026 | FDA's advisory committee votes 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A list, and the same for TB-500 and KPV |
| Next | FDA rulemaking, typically six to twelve months. Until it completes, neither is on the list |
Listed alone would not mean listed together
If FDA adds both peptides, a pharmacy could compound each on a prescription. It could not sell the blend, because compounded preparations are made to a prescriber's order for a patient, not to a vendor's recipe. Whatever the rulemaking brings, the vial sold as Wolverine stays a research-chemical product.
- FDA's 2023 concern was about the product as much as the molecule: unverified purity, synthesis impurities, and the immune reactions they provoke. A blend carries two syntheses' worth.
- "Research use only" on the label protects the seller. FDA's 2025 and 2026 letters cited dosing charts and bacteriostatic water sold alongside as evidence of intended human use.
- For an athlete, one injection of the blend is two prohibited substances, and TB-500's detection window runs for weeks.
Reading a blend vial: the arithmetic10
A 1:1 blend is the simplest case of the blend problem: every dose is half one peptide and half the other, so each peptide's dose is half the number on the syringe. That is easy to remember and easy to forget when a protocol written for BPC-157 alone is applied to the blend.
units = (blend dose mcg ÷ blend concentration mcg/mL) × 100; each peptide gets half
A 20 mg vial (20,000 mcg of blend) with 2 mL of water is 10,000 mcg/mL. A 10-unit draw is 0.1 mL, which is 1 mg of blend: 500 mcg of BPC-157 and 500 mcg of TB-500.
| Water added | Blend concentration | 6 units | 10 units | 20 units |
|---|---|---|---|---|
| 1 mL | 20 mg/mL | 600 mcg each | 1 mg each | 2 mg each |
| 2 mL | 10 mg/mL | 300 mcg each | 500 mcg each | 1 mg each |
| 3 mL | 6.7 mg/mL | 200 mcg each | 333 mcg each | 667 mcg each |
A 10 + 10 mg vial with 1 mL of water and a 20-unit draw delivers 2 mg of TB-500, a full loading dose, and 2 mg of BPC-157, four to eight times its usual dose, in one injection. Ratios and water volumes change both numbers at once.
Neither peptide has been shown to be dangerous, and neither has been shown to be safe, because the studies that would show either have not been done. The full thymosin beta-4 protein has a reassuring safety record at intravenous doses far above anything in a vial; the fragment has not been given to a person in a study.
- Reported
- No serious adverse events in the three small BPC-157 reports. Anecdotally for both: injection-site irritation, nausea, dizziness, fatigue, a feeling of head pressure after TB-500.
- Attribution
- With two peptides in one syringe, a reaction cannot be traced to either. The only remedy is stopping both.
- Shared mechanism
- Both promote new blood-vessel growth and cell migration, the programs tumors depend on. No study has examined either in people with cancer or a cancer history, and the blend doubles the concern.
- Product
- FDA's stated concern for BPC-157: immunogenicity and impurities. Two syntheses in one vial, mixed and freeze-dried without a stability study.
- Sterility
- Research-chemical vials are not certified sterile or endotoxin-free, and a blend vial is punctured nightly for a month.
- Unknown
- Pregnancy, adolescents, use with other medicines, and anything beyond a few weeks.
- Athletes
- Two prohibited substances per injection; a positive test at any time, with TB-500 detectable for weeks.
- Which of the two am I buying this for, and what is the human evidence for it? (BPC-157: three uncontrolled reports. TB-500: none.)
- Is either on FDA's compounding list yet? Who made this vial, and under what authority?
- At my water volume and draw, how much of each peptide am I injecting per night and per week?
- If something goes wrong, how will I know which peptide caused it?
- Can the seller show a certificate of analysis for this lot with identity, ratio, and sterility?
- Do I have a cancer history? Am I subject to anti-doping rules at work or in sport?
- What proven treatment for this injury am I delaying, and what is the plan if nothing changes in eight weeks?
What does have evidence for tendon, ligament, and muscle injury
Progressive loading under a physical therapist, sleep and protein sufficiency, and time. For a surgical repair, the surgeon's rehabilitation protocol. Less glamorous than a superhero, and the only things shown to work in controlled human trials.
Latest
Developments since this edition, newest first. Items here are dated and sourced; they update the guide without re-editing it.
UCLA review of 565 studies finds almost no human evidence for six popular recovery peptides
Orthopedic researchers reviewed 565 studies of BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, and GHK-Cu for muscle, tendon, and joint use (American Journal of Sports Medicine, 2026). More than two-thirds were animal-only, and the authors found essentially no studies showing a significant clinical benefit for musculoskeletal conditions.
Health Affairs: the vote may open a compounding back door
A policy commentary argues the committee narrowly backed BPC-157 and TB-500 despite no evidence of clinical benefit, and that listing them would exempt them from premarket review and manufacturing standards.
Six of seven peptides recommended; rulemaking still required
BPC-157 and TB-500 were among the six the committee recommended, with emideltide rejected. No proposed rule or list change followed the meeting, and none has as of this update.
Attorneys estimate 8 to 12 months of rulemaking before pharmacies have authority
Day-one tallies were 8 to 6 with one abstention for BPC-157, KPV, and TB-500, and 7 to 5 with two abstentions for MOTS-c. A quoted attorney expects most of a year before 503A pharmacies could compound any of them.
References
- 1.Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- 2.Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- 3.Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024.
- 4.Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025.
- 5.Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci. 2007;1112:407-412. https://pubmed.ncbi.nlm.nih.gov/17495250/
- 6.Sosne G, et al. 0.1% RGN-259 (thymosin beta-4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2023;24(1):558. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
- 7.U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (BPC-157, TB-500, KPV, MOTS-c, epitalon, semax recommended). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 8.U.S. Food and Drug Administration. Bulk drug substances nominated for compounding under section 503A: Category 2 (BPC-157, September 2023); withdrawals including BPC-157 and TB-500 (April 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- 9.World Anti-Doping Agency. The Prohibited List 2026: S0 (BPC-157) and thymosin beta-4 derivatives including TB-500; U.S. Anti-Doping Agency on BPC-157. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- 10.Representative BPC-157 / TB-500 blend listings and reconstitution instructions from research-chemical vendors, as sold September 2026 (20 mg vial, 2 mL, 6 to 10 units nightly). https://www.peptidedosingprotocols.com/stacks/wolverine-stack